With the increase in use of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) in the population, nuclear medicine physicians should be aware of the possibility of nondiagnostic FDG PET scans due to these medications, which work partly by increasing insulin secretion. We demonstrate a case where a patient's use of such a medication presumptively led to muscular and myocardial uptake, complicating scan interpretation considerably. Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.
Keyphrases
- pet imaging
- pet ct
- positron emission tomography
- computed tomography
- case report
- type diabetes
- primary care
- healthcare
- magnetic resonance imaging
- left ventricular
- palliative care
- heart failure
- emergency department
- human health
- skeletal muscle
- climate change
- metabolic syndrome
- insulin resistance
- contrast enhanced
- dual energy